Business context and reporting period
This is Sonim Technologies, Inc.’s Form 10-K for the fiscal year ended December 31, 2021—not a quarterly filing. The request metadata names “DNA X, Inc.,” but the filing identifies Sonim Technologies, Inc. (Nasdaq: SONM). Sonim sells rugged mobile phones, accessories and related software, primarily through wireless carriers, for industrial and public-sector users. The filing reports one operating segment.
Sonim sold approximately 229,000 units in 2021, versus 255,000 in 2020. Smartphones generated $14.8 million of revenue and feature phones $37.7 million. Approximately 90% of revenue came from large wireless carriers; the top four customers accounted for 76% of revenue in both years.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $54.6 million | $64.0 million |
| Gross profit / margin | $6.4 million / 11.8% | $15.2 million / 23.8% |
| Operating loss | $38.0 million | $29.3 million |
| Net loss | $38.6 million | $29.9 million |
| Adjusted EBITDA (non-GAAP) | $(34.7) million | $(24.3) million |
| Cash used in operating activities | $38.5 million | $10.6 million |
| Cash and cash equivalents at year-end | $11.2 million | $22.1 million |
Revenue declined 14.7%, while gross profit fell 57.8%; the deterioration reflected lower XP8 sales and an unfavorable product mix. Operating expenses were broadly flat at $44.4 million. Research and development rose to $17.7 million as Sonim developed new products; legal expense was $6.9 million, primarily related to the SEC investigation.
At December 31, 2021, total assets were $41.1 million, current assets $35.7 million and current liabilities $21.0 million. Total liabilities were $22.5 million and stockholders’ equity $18.6 million. Long-term debt and its current portion totaled approximately $214,000; the company stated it had no other borrowing structures in place. It used $38.5 million in operating cash and raised $27.7 million net through at-the-market (ATM) share sales, ending the year with $11.2 million in cash. Cash was approximately $9.8 million on February 28, 2022. The ATM program had approximately $21.6 million of capacity remaining at year-end.
Material changes versus the prior year
- Revenue fell $9.4 million, mainly as XP8 smartphone sales declined 35% and legacy products reached end of life. Smartphone unit sales decreased 43%; feature-phone unit sales decreased 3%.
- Gross margin dropped 12 percentage points to 11.8%. The 2020 mix included more higher-margin XP8 sales.
- Net loss increased $8.7 million, and operating cash use increased $27.9 million.
- Sonim outsourced substantially all manufacturing, software development and quality-control work, and reduced year-end staffing to 77 employees and 25 contractors, from 263 employees and 54 contractors a year earlier.
- Sonim issued 12.1 million shares during 2021, primarily through ATM offerings, and completed a 1-for-10 reverse stock split. The share count at year-end was 18.8 million, versus 6.6 million at the end of 2020, as presented retrospectively for the split.
Outlook, risks, contingencies and unusual items
Management disclosed substantial doubt about Sonim’s ability to continue as a going concern for at least one year from issuance of the financial statements. It expects operating losses to continue and says further financing may be needed. Management is evaluating funding alternatives, including equity, debt, mezzanine financing and strategic partners; it cautions that financing may not be available on acceptable terms or at all.
Sonim expected to launch the XP5plus and XP10 in the third quarter of 2022, replacing the XP5s and XP8, and expected the next-generation phones to contribute significantly to revenue by year-end 2022. These are expectations, not guaranteed outcomes. The filing provides no quantified revenue or earnings guidance. Product-development commitments were approximately $6.5 million at year-end; noncancelable inventory and other purchase orders were approximately $5.7 million. The filing also cites approximately $4.0 million in software-developer contractual obligations and $2.3 million in operating lease commitments.
- Liquidity and dilution: Continuing losses, cash burn, product-development needs and reliance on additional capital create material funding risk. ATM equity issuance diluted existing shareholders.
- Nasdaq listing: Sonim received a February 2022 deficiency notice for trading below the $1.00 minimum bid price, with until August 15, 2022 to regain compliance; delisting remained possible.
- Legal matters: The SEC investigation remained ongoing, with resolution discussions underway from October 2021. Sonim could not estimate a potential loss range and had recorded no litigation reserve. A previously filed IPO-related class action settlement of $2.0 million had been paid; derivative litigation remained pending.
- Controls: Management reported ineffective disclosure controls and a material weakness involving IT general controls, including excessive administrator access to financial-reporting systems. Remediation was expected in the second half of 2022.
- Operating risks: Revenue concentration, nonbinding customer forecasts, carrier certification requirements, reliance on third-party manufacturers and suppliers, and single-source components expose results to customer, production and supply disruptions.
- Other pressures: COVID-19-related supply delays and higher shipping costs continued; inventory write-downs were $1.6 million in 2021. Sonim also faces intense competition, product-transition risk and potential costs from securities matters and indemnification obligations.
Important facts for investors to verify
- Post-year-end cash, monthly cash burn, financing availability and the company’s ability to fund operations through the next product launches.
- Actual timing, carrier certification, market acceptance and sales of the XP5plus and XP10, including whether new products offset declining legacy-product revenue.
- Progress toward Nasdaq bid-price compliance and any effects of further share issuance or a reverse split.
- Developments and potential financial exposure from the SEC investigation and pending derivative litigation.
- Remediation and independent testing of the disclosed IT-controls material weakness.
- Customer concentration, receivable collectability and production continuity under outsourced manufacturing and supplier arrangements.